Humana Inc. (NYSE:HUM) Position Increased by NEOS Investment Management LLC

NEOS Investment Management LLC raised its position in Humana Inc. (NYSE:HUM - Free Report) by 27.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,697 shares of the insurance provider's stock after buying an additional 1,241 shares during the period. NEOS Investment Management LLC's holdings in Humana were worth $1,445,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of HUM. Dynamic Technology Lab Private Ltd acquired a new stake in Humana during the 3rd quarter valued at approximately $404,000. Glenmede Trust Co. NA grew its position in shares of Humana by 7.6% during the third quarter. Glenmede Trust Co. NA now owns 25,718 shares of the insurance provider's stock worth $8,146,000 after buying an additional 1,813 shares in the last quarter. CreativeOne Wealth LLC bought a new stake in shares of Humana in the third quarter worth $208,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Humana by 1.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 856,954 shares of the insurance provider's stock valued at $271,432,000 after acquiring an additional 9,100 shares in the last quarter. Finally, Public Sector Pension Investment Board boosted its stake in Humana by 13.0% during the 3rd quarter. Public Sector Pension Investment Board now owns 5,222 shares of the insurance provider's stock valued at $1,654,000 after acquiring an additional 600 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of the firm's stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares of the company's stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.37% of the stock is owned by insiders.

Remove Ads

Humana Stock Performance

Humana stock traded down $0.23 during mid-day trading on Monday, hitting $264.35. 1,201,515 shares of the company's stock traded hands, compared to its average volume of 1,756,635. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The company has a market cap of $31.91 billion, a PE ratio of 26.57, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The firm has a 50 day moving average price of $269.77 and a 200 day moving average price of $273.07. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, equities analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date is Friday, March 28th. Humana's payout ratio is currently 35.58%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HUM. Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Royal Bank of Canada restated an "outperform" rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Barclays lifted their target price on Humana from $255.00 to $270.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 13th. Morgan Stanley dropped their price target on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Eighteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.